


UBS Equity Biotech

Performance Review

UBS (Lux) Equity Fund - Biotech (USD) P-acc



Performance (basis USD, net of fees)¹



Past performance is not a reliable indicator of future results.

Performance in % (net of fees)¹

in %	2019	2020	2021	2022	2023 YTD ²	Apr. 2023	5 years Ø p.a. 5 years
Fund (USD)	26.26	24.61	-5.63	-8.31	-3.41	0.63	22.57
Ref. Index ³	24.21	28.24	0.05	-2.60	-0.35	1.02	44.28

The performance shown does not take account of any commissions, entry or exit charges.

¹ These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.

² YTD: year-to-date (since beginning of the year)

³ Reference Index in currency of share class (without costs)

Biotech markets were relatively range-bound this month, with the notable exceptions being a resurgence in high-profile M&A activity: Merck announced a planned USD 11bn acquisition of Prometheus, while rumours surrounding IVERIC were put to rest with the confirmation of the USD 5.9bn takeover by Astellas on 1 May.

Monthly performance

In April the fund performed positively with 0.6%. The fund's performance relative to the broad biotech sector was primarily driven by not owning several names that materially outperformed on M&A news.

YTD performance

YTD as of the end of April, the fund has delivered a negative performance of 3.4%. The fund's underperformance relative to the sector in the year to date has largely been driven by headwinds in the biotech capital markets funding environment, which has weighed particularly heavily on longer duration, highly innovative names that we still expect will materially outperform over the longer term.

Performance contributors

Contributors in April included Arrowhead, IVERIC and Genmab. Arrowhead outperformed following positive Phase I data for its RNAi drug. IVERIC rose on acquisition rumours, while Genmab traded higher after J&J earnings indicated positive growth in the partnership DARZALEX franchise.

Performance detractors

Negative contributions came from Moderna and Relay, as well as not owning Prometheus after the USD 11bn Merck deal was announced.

For more information

UBS Fund Infoline: 0800 899 899

Internet: www.ubs.com/funds

Contact your client advisor

Portfolio management representatives

Sara Cotter

Matthew Konosky

Caroline Wallace

UBS Equity Biotech

Market exposure (%)

	Fund
United States	79.70
Denmark	5.15
Switzerland	2.69
United Kingdom	2.63
Germany	2.56
Netherlands	2.43
Ireland	1.91
Canada	1.88
Sweden	1.05

10 largest equity positions (%)

	Fund
Regeneron Pharmaceuticals Inc	9.28
Alnylam Pharmaceuticals Inc	8.51
Moderna Inc	6.44
Seagen Inc	6.00
Vertex Pharmaceuticals Inc	5.14
Gilead Sciences Inc	4.58
AbbVie Inc	4.43
Genmab A/S	3.96
Neurocrine Biosciences Inc	3.63
Karuna Therapeutics Inc	3.55

Current investment strategy

While we are maintaining exposure to larger pharma in order to diversify risk, we remain constructive on SMID cap names with a robust pipeline. Easing financial conditions over the latter half of 2023 should be a particular tailwind for the smaller end of the market, and we have added to select holdings on near-term price dislocation.

Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary. © UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.